Premier Fund Managers Ltd Purchases 20,099 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Key Points

• Premier Fund Managers Ltd increased its holdings in IQVIA Holdings Inc. by 8.7%, now owning approximately $44.35 million worth of the stock, which represents 1.7% of their investment portfolio.
• Insider Eric Sherbet sold 5,800 shares at an average price of $190.05, resulting in a decrease of 17.59% in their ownership.
• Analysts have mixed ratings on IQVIA, with a consensus average rating of "Moderate Buy" and a price target of $228.62, reflecting a varied outlook on the stock's performance.

Premier Fund Managers Ltd boosted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 8.7% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 250,099 shares of the medical research company's stock after acquiring an additional 20,099 shares during the quarter. IQVIA accounts for about 1.7% of Premier Fund Managers Ltd's investment portfolio, making the stock its 26th largest holding. Premier Fund Managers Ltd owned 0.14% of IQVIA worth $44,347,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of IQV. Brighton Jones LLC raised its stake in shares of IQVIA by 244.4% during the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company's stock worth $703,000 after purchasing an additional 2,537 shares in the last quarter. LPL Financial LLC raised its stake in shares of IQVIA by 1.4% in the 4th quarter. LPL Financial LLC now owns 96,506 shares of the medical research company's stock valued at $18,964,000 after acquiring an additional 1,311 shares in the last quarter. Blair William & Co. IL increased its position in IQVIA by 42.0% in the 4th quarter. Blair William & Co. IL now owns 5,742 shares of the medical research company's stock worth $1,128,000 after buying an additional 1,699 shares during the period. Pictet Asset Management Holding SA increased its position in IQVIA by 12.7% in the 4th quarter. Pictet Asset Management Holding SA now owns 105,227 shares of the medical research company's stock worth $20,678,000 after buying an additional 11,839 shares during the period. Finally, Brown Brothers Harriman & Co. increased its position in IQVIA by 468.3% in the 4th quarter. Brown Brothers Harriman & Co. now owns 466 shares of the medical research company's stock worth $92,000 after buying an additional 384 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Price Performance

IQVIA stock traded down $3.58 during mid-day trading on Friday, reaching $182.28. 1,014,477 shares of the company were exchanged, compared to its average volume of 2,029,829. The company has a fifty day simple moving average of $161.20 and a 200-day simple moving average of $170.18. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $252.88. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. The firm has a market cap of $30.99 billion, a PE ratio of 26.45, a PEG ratio of 2.10 and a beta of 1.30.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping analysts' consensus estimates of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%. The firm had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. During the same quarter last year, the company earned $2.64 EPS. The company's revenue was up 5.3% on a year-over-year basis. As a group, equities research analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Keriann Cherofsky sold 549 shares of the business's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the transaction, the insider owned 2,910 shares of the company's stock, valued at approximately $557,352.30. The trade was a 15.87% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Eric Sherbet sold 5,800 shares of the business's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the transaction, the insider directly owned 27,178 shares of the company's stock, valued at $5,165,178.90. This trade represents a 17.59% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

IQV has been the topic of several recent research reports. William Blair reissued an "outperform" rating on shares of IQVIA in a report on Wednesday, July 23rd. Evercore ISI boosted their price objective on IQVIA from $170.00 to $180.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 9th. JPMorgan Chase & Co. reduced their price objective on IQVIA from $232.00 to $177.00 and set an "overweight" rating on the stock in a research note on Monday, May 19th. Robert W. Baird boosted their price objective on IQVIA from $159.00 to $196.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 23rd. Finally, Citigroup reaffirmed a "neutral" rating on shares of IQVIA in a research note on Thursday, May 22nd. Seven investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $228.62.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.